SAM
CYTK icon

Silphium Asset Management’s Cytokinetics CYTK Stock Holding History

Silphium Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,000
Closed -$1.85M – 61
2024
Q3 		$1.85M Buy
35,000
+25,000
+250% +$1.39M 0.66% 44
2024
Q2 		$542K Buy
+10,000
New +$604K 0.26% 50

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Silphium Asset Management's CYTK Position: Q1 2025 in Review

Silphium Asset Management sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 30,000 shares — an estimated $1.41M sold.

Silphium Asset Management first reported a position in CYTK in Q4 2023 and held it in 5 quarters. The position peaked at $5.2M in Q3 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • Silphium Asset Management reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • Silphium Asset Management sold 30,000 Cytokinetics shares in Q1 2025, an estimated $1.41M.
  • Silphium Asset Management first reported a position in Cytokinetics in Q4 2023 and held it in 5 quarters.
  • Silphium Asset Management's Cytokinetics position peaked at $5.2M in Q3 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on Silphium Asset Management's 13F filing for Q1 2025, filed 30 Apr 2025.